Incarceration history is associated with HIV infection among community-recruited people who inject drugs in Europe: A propensity-score matched analysis of cross-sectional studies
Jazyk angličtina Země Velká Británie, Anglie Médium print-electronic
Typ dokumentu časopisecké články, práce podpořená grantem
Grantová podpora
WT 226619/Z/22/Z
Wellcome Trust - United Kingdom
Odkazy
PubMed
37991429
DOI
10.1111/add.16283
Knihovny.cz E-zdroje
- Klíčová slova
- Europe, HIV, PWID, incarceration, injection drug use, prison,
- MeSH
- HIV infekce * epidemiologie MeSH
- HIV séropozitivita * MeSH
- intravenózní abúzus drog * epidemiologie MeSH
- lidé MeSH
- průřezové studie MeSH
- tendenční skóre MeSH
- uživatelé drog * MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Geografické názvy
- Evropa epidemiologie MeSH
AIMS: We measured the association between a history of incarceration and HIV positivity among people who inject drugs (PWID) across Europe. DESIGN, SETTING AND PARTICIPANTS: This was a cross-sectional, multi-site, multi-year propensity-score matched analysis conducted in Europe. Participants comprised community-recruited PWID who reported a recent injection (within the last 12 months). MEASUREMENTS: Data on incarceration history, demographics, substance use, sexual behavior and harm reduction service use originated from cross-sectional studies among PWID in Europe. Our primary outcome was HIV status. Generalized linear mixed models and propensity-score matching were used to compare HIV status between ever- and never-incarcerated PWID. FINDINGS: Among 43 807 PWID from 82 studies surveyed (in 22 sites and 13 countries), 58.7% reported having ever been in prison and 7.16% (n = 3099) tested HIV-positive. Incarceration was associated with 30% higher odds of HIV infection [adjusted odds ratio (aOR) = 1.32, 95% confidence interval (CI) = 1.09-1.59]; the association between a history of incarceration and HIV infection was strongest among PWID, with the lowest estimated propensity-score for having a history of incarceration (aOR = 1.78, 95% CI = 1.47-2.16). Additionally, mainly injecting cocaine and/or opioids (aOR = 2.16, 95% CI = 1.33-3.53), increased duration of injecting drugs (per 8 years aOR = 1.31, 95% CI = 1.16-1.48), ever sharing needles/syringes (aOR = 1.91, 95% CI = 1.59-2.28) and increased income inequality among the general population (measured by the Gini index, aOR = 1.34, 95% CI = 1.18-1.51) were associated with a higher odds of HIV infection. Older age (per 8 years aOR = 0.84, 95% CI = 0.76-0.94), male sex (aOR = 0.77, 95% CI = 0.65-0.91) and reporting pharmacies as the main source of clean syringes (aOR = 0.72, 95% CI = 0.59-0.88) were associated with lower odds of HIV positivity. CONCLUSIONS: A history of incarceration appears to be independently associated with HIV infection among people who inject drugs (PWID) in Europe, with a stronger effect among PWID with lower probability of incarceration.
Agència de Salut Pública de Barcelona Barcelona Spain
Blood Safety Hepatitis STI and HIV Division UK Health Security Agency London UK
Department of Computational Biology University of Lausanne Lausanne Switzerland
Department of Infection and Immunity Luxembourg Institute of Health Luxembourg
Department of Infectious Diseases Public Health Service of Amsterdam Amsterdam the Netherlands
EMCDDA Polish National Focal Point National Bureau for Drug Prevention Warsaw Poland
EPIUnit Instituto de Saúde Pública Universidade do Porto Porto Portugal
European Monitoring Centre for Drugs and Drug Addiction Lisbon Portugal
Finnish Institute for Health and Welfare Helsinki Finland
Hungarian Reitox National Focal Point Budapest Hungary
Institute of Family Medicine and Public Health University of Tartu Tartu Estonia
Institute of Public Health Riga Stradins University Riga Latvia
Klinika Podané ruce Brno Czech Republic
National Drug and Alcohol Research Centre the University of New South Wales Sydney NSW Australia
National Institute for Infectious diseases 'Professor Dr Matei Bals' Bucharest Romania
National Public Health Center Budapest Hungary
National Research University Higher School of Economics St Petersburg Russia
National School of Public Health Carlos 3 Health Institute Madrid Spain
Non Profit Partnership ESVERO 12 Moscow Russia
Population Health Sciences Bristol Medical School University of Bristol Bristol UK
Public Health Institute Liverpool John Moores University Liverpool UK
Public Health Scotland Meridian Court Glasgow Scotland UK
School of Global Public Health New York University New York NY 10012 USA
School of Health and Life Sciences Glasgow Caledonian University Glasgow Scotland UK
Service National des Maladies Infectieuses Centre Hospitalier de Luxembourg Luxembourg
Sayyah M, Rahim F, Kayedani GA, Shirbandi K, Saki‐Malehi A. Global view of HIV prevalence in prisons: a systematic review and meta‐analysis. Iran J Public Health. 2019;48:217–226.
Dolan K, Moazen B, Noori A, Rahimzadeh S, Farzadfar F, Hariga F. People who inject drugs in prison: HIV prevalence, transmission and prevention. Int J Drug Policy. 2015;26:S12–S15.
European Monitoring Centre for Drugs and Drug Addiction. Prison and drugs in Europe: current and future challenges. Publications Office of the European Union, Luxembourg; 2021.
Kivimets K, Uuskula A, Lazarus JV, Ott K. Hepatitis C seropositivity among newly incarcerated prisoners in Estonia: data analysis of electronic health records from 2014 to 2015. BMC Infect Dis. 2018;18:339.
Degenhardt L, Peacock A, Colledge S, Leung J, Grebely J, Vickerman P, et al. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. Lancet Glob Health. 2017;5:e1192–e1207.
Wiessing L, Kalamara E, Stone J, Altan P, van Baelen L, Fotiou A, et al. Univariable associations between a history of incarceration and HIV and HCV prevalence among people who inject drugs across 17 countries in Europe 2006 to 2020 ‐ is the precautionary principle applicable? Euro Surveill. 2021;26:2002093.
The EMIS Network. EMIS‐2017—The European Men‐Who‐Have‐Sex‐With‐Men Internet Survey. Key findings from 50 countries Stockholm: European Centre for Disease Prevention and Control; 2019 Available at: https://www.esticom.eu/Webs/ESTICOM/EN/emis-2017/survey-report/EMIS_2017_REPORT_ECDC.pdf?__blob=publicationFile&v=1. Accessed 15 May 2023.
European Centre for Disease Prevention and Control (ECDC). Thematic report: Sex workers. Monitoring implementation of the Dublin Declaration on Partnership to Fight HIV/AIDS in Europe and Central Asia: 2012 progress report Stockholm: ECDC; 2013 Available at: https://www.ecdc.europa.eu/sites/default/files/media/en/publications/Publications/dublin-declaration-sex-workers.pdf. Accessed 15 May 2023.
van der Meulen E. ‘It goes on everywhere’: injection drug use in Canadian Federal Prisons. Subst Use Misuse. 2017;52:884–891.
Koulierakis G, Gnardellis C, Agrafiotis D, Power KG. HIV risk behaviour correlates among injecting drug users in Greek prisons. Addiction. 2000;95:1207–1216.
Izenberg JM, Bachireddy C, Wickersham JA, Soule M, Kiriazova T, Dvoriak S, et al. Within‐prison drug injection among HIV‐infected Ukrainian prisoners: prevalence and correlates of an extremely high‐risk behaviour. Int J Drug Policy. 2014;25:845–852.
Dolan K, Wirtz AL, Moazen B, Ndeffo‐mbah M, Galvani A, Kinner SA, et al. Global burden of HIV, viral hepatitis, and tuberculosis in prisoners and detainees. Lancet. 2016;388:1089–1102.
Vaitkevičiūtė I. HIV outbreak 2016—role of prison; 2017. Available at: http://www.emcdda.europa.eu/system/files/attachments/4663/HIVOutbreak2017‐roleofprison%28Alytusprisoninparticular%29%2CresponsesinplaceIevaVaitkeviciute%2CLithuania.pdf. Accessed 15 May 2023.
Stone J, Fraser H, Lim AG, Walker JG, Ward Z, MacGregor L, et al. Incarceration history and risk of HIV and hepatitis C virus acquisition among people who inject drugs: a systematic review and meta‐analysis. Lancet Infect Dis. 2018;18:1397–1409.
Cepeda JA, Niccolai LM, Lyubimova A, Kershaw T, Levina O, Heimer R. High‐risk behaviors after release from incarceration among people who inject drugs in St. Petersburg, Russia. Drug Alcohol Depend. 2015;147:196–202.
Iroh PA, Mayo H, Nijhawan AE. The HIV care Cascade before, during, and after incarceration: a systematic review and data synthesis. Am J Public Health. 2015;105:e5–e16.
Rich JD, Beckwith CG, Macmadu A, Marshall BDL, Brinkley‐Rubinstein L, Amon JJ, et al. Clinical care of incarcerated people with HIV, viral hepatitis, or tuberculosis. Lancet. 2016;388:1103–1114.
Stöver H, Tarján A, Horváth G, Montanari L. The state of harm reduction in prisons in 30 European countries with a focus on people who inject drugs and infectious diseases. Harm Reduct J. 2021;18:67.
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Prison and drugs in Europe: current and future challenges Luxembourg: Publications Office of the European Union; 2022.
Kretzschmar M, Wiessing L. Coordination of a working group to develop mathematical and statistical models and analyses of protective factors for HIV infection among injecting drug users. Technical report. Luxembourg: European Monitoring Centre for Drugs and Drug Addiction (EMCDDA); 2007.
Uusküla A, Raag M, Folch C, Prasad L, Karnite A, van Veen MG, et al. Self‐reported testing, HIV status and associated risk behaviours among people who inject drugs in Europe: important differences between east and west. AIDS. 2014;28:1657–1664.
van Buuren S. Flexible Imputation of Missing Data, 2nd edition. 2018. Available at: https://stefvanbuuren.name/fimd/sec-MCAR.html. Accessed 15 May 2023.
Rosenbaum PR, Rubin DB. The central role of the propensity‐score in observational studies for causal effects. Biometrika. 1983;70:41–55.
Stuart EA. Matching methods for causal inference: a review and a look forward. Stat Sci. 2010;25:1–21.
Austin PC. Statistical criteria for selecting the optimal number of untreated subjects matched to each treated subject when using many‐to‐one matching on the propensity‐score. Am J Epidemiol. 2010;172:1092–1097.
Eritsyan KU, Levina OS, White E, Smolskaya TT, Heimer R. HIV prevalence and risk behavior among injection drug users and their sex partners in two Russian cities. AIDS Res Hum Retroviruses. 2013;29:687–690.
Vorobjov S, Uusküla A, Abel‐Ollo K, Talu A, Rüütel K, Des Jarlais DC. Comparison of injecting drug users who obtain syringes from pharmacies and syringe exchange programs in Tallinn, Estonia. Harm Reduct J. 2009;6:3.
Hser YI, Anglin MD, Grella C, Longshore D, Prendergast ML. Drug treatment careers. A conceptual framework and existing research findings. J Subst Abuse Treat. 1997;14:543–558.
Kral AH, Bluthenthal RN, Booth RE, Watters JK. HIV seroprevalence among street‐recruited injection drug and crack cocaine users in 16 US municipalities. Am J Public Health. 1998;88:108–113.
McAuley A, Palmateer NE, Goldberg DJ, Trayner KMA, Shepherd SJ, Gunson RN, et al. Re‐emergence of HIV related to injecting drug use despite a comprehensive harm reduction environment: a cross‐sectional analysis. Lancet HIV. 2019;6:e315–e324.
Arendt V, Guillorit L, Origer A, Sauvageot N, Vaillant M, Fischer A, et al. Injection of cocaine is associated with a recent HIV outbreak in people who inject drugs in Luxembourg. PLOS ONE. 2019;14:e0215570.
Valencia J, Alvaro‐Meca A, Troya J, Cuevas G, Gutiérrez J, Morro A, et al. High rates of early HCV reinfection after DAA treatment in people with recent drug use attended at mobile harm reduction units. Int J Drug Policy. 2019;72:181–188.
United Nations Office on Drugs and Crime (UNODC). Systematic literature review on HIV and stimulant drugs use. (A) Part 4/5. NPS and HIV risk and transmission Vienna, UNODC; 2017.
Des Jarlais DC, Feelemyer JP, Modi SN, Arasteh K, Hagan H. Are females who inject drugs at higher risk for HIV infection than males who inject drugs: an international systematic review of high seroprevalence areas. Drug Alcohol Depend. 2012;124:95–107.
Sypsa V, Psichogiou M, Paraskevis D, Nikolopoulos G, Tsiara C, Paraskeva D, et al. Rapid decline in HIV incidence among persons who inject drugs during a fast‐track combination prevention program after an HIV outbreak in Athens. J Infect Dis. 2017;215:1496–1505.
Ghiasvand H, Bayani A, Noroozi A, Marshall BD, Koohestani HR, Hemmat M, et al. Comparing injecting and sexual risk behaviors of long‐term injectors with new injectors: a meta‐analysis. J Addict Dis. 2018;37:233–244.
Nikolopoulos GK, Fotiou A, Kanavou E, Richardson C, Detsis M, Pharris A, et al. National income inequality and declining GDP growth rates are associated with increases in HIV diagnoses among people who inject drugs in Europe: a panel data analysis. PLOS ONE. 2015;10:e0122367.
Larney S, Leung J, Grebely J, Hickman M, Vickerman P, Peacock A, et al. Global systematic review and ecological analysis of HIV in people who inject drugs: national population sizes and factors associated with HIV prevalence. Int J Drug Policy. 2020;77:102656.
McCusker J, Stoddard AM, McCarthy E. The validity of self‐reported HIV antibody test results. Am J Public Health. 1992;82:567–569.
Stevens A, Hughes CE, Hulme S, Cassidy R. Depenalization, diversion and decriminalization: a realist review and programme theory of alternatives to criminalization for simple drug possession. Eur J Criminol. 2022;19:29–54.
Wilson SJ, Lemoine J. Methods of calculating the marginal cost of incarceration: a scoping review. Crim Justice Policy Rev. 2022;33:639–663.
Ward Z, Stone J, Bishop C, Ivakin V, Eritsyan K, Deryabina A, et al. Costs and impact on HIV transmission of a switch from a criminalisation to a public health approach to injecting drug use in eastern Europe and Central Asia: a modelling analysis. Lancet HIV. 2022;9:e42–e53.